WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...
Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
UroLift is a minimally invasive treatment for Benign Prostatic Hyperplasia, a condition that causes an enlarged prostate in men. The procedure uses tiny implants to lift and hold the enlarged prostate ...
Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) - Additional studies examine ...
Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System as a leading minimally invasive treatment for benign ...
WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift ® System, a proven, minimally ...
The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.
In a ground-breaking medical achievement, Nigeria has become the first country in West and Central Africa to successfully perform the UroLift procedure, a revolutionary treatment for benign prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback